All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Revisit Every OncLive On Air Episode From December 2024

January 3rd 2025

In case you missed any, read a recap of the episodes of OncLive On Air that aired in December 2024.

Distinctions Between Alteration Types, Therapeutic Classes Could Drive Optimal Treatment Selection in HER2-Mutant NSCLC

January 3rd 2025

Nicolas Girard, MD, compares the predictive value, mechanisms of action, and safety or efficacy profile of HER2-targeted TKIs vs ADCs in NSCLC.

Roswell Park Team Discovers New Treatment Target for Neuroendocrine Prostate Cancer

January 3rd 2025

Data published in Oncogene suggest that the mitochondrial unfolded protein response could be an Achilles’ heel for neuroendocrine prostate cancer.

Satri-Cel Improves PFS in Pretreated CLDN18.2+ Advanced Gastric/GEJ Cancer

January 3rd 2025

Satri-cel improved PFS vs investigator’s choice of therapy in pretreated CLDN18.2-positive advanced gastric/GEJ cancer.

Taletrectinib Approved in China for Locally Advanced/Metastatic ROS1+ NSCLC

January 3rd 2025

China's NMPA has approved taletrectinib adipate capsule for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC.

A Continuous Race of Biomarker Research and Molecular Strategies

January 3rd 2025

Through prolific biomarker research, Fabrice André, MD, PhD, has worked throughout his career to make strides in personalized breast cancer care.

Tremelimumab Plus Paclitaxel Generates Responses in Refractory Metastatic Urothelial Cancer

January 3rd 2025

Tremelimumab plus paclitaxel induced responses in metastatic urothelial cancer after progression on platinum and an immune checkpoint inhibitor.

One Surgeon’s Spirit and Brilliance Lift a Whole Community

January 3rd 2025

A childhood dream became a reality for Montana native Kelly K. Hunt, MD, FACS, FSSO, who has changed the face of the surgical breast oncology workforce.

Pembrolizumab Plus SBRT Fails to Improve Survival in Unresected Stage I/II NSCLC

January 2nd 2025

The addition of pembrolizumab to radiation did not improve survival in unresected, stage I or II non–small cell lung cancer.

Generic Platinum Chemotherapy Shortages Did Not Increase Deaths

January 2nd 2025

A national data analysis published by researchers from Penn Medicine reported that short-term mortality was not impacted for patients with advanced cancers during the shortage of generic platinum chemotherapy drugs.

Savolitinib Plus Osimertinib Receives Priority Review in China for Pretreated EGFR+ NSCLC With a MET Amplification

January 2nd 2025

China’s NMPA has granted priority review to the NDA for savolitinib plus osimertinib in pretreated EGFR-mutated advanced NSCLC with MET amplification.

European Commission Approves Lazertinib Plus Amivantamab in First-Line EGFR-Mutated NSCLC

January 2nd 2025

The European Commission has approved a type II variation extended indication for lazertinib plus amivantamab in frontline EGFR-mutated NSCLC.

FDA Approval Sought for Dordaviprone in Recurrent H3K27M+ Diffuse Glioma

January 2nd 2025

A NDA has been submitted to the FDA seeking the approval of dordaviprone for recurrent H3K27M-mutant diffuse glioma.

FDA Grants Priority Review to Avutometinib Plus Defactinib for KRAS+ Recurrent Low-Grade Serous Ovarian Cancer

January 2nd 2025

The FDA has granted priority review to the NDA for avutometinib plus defactinib in KRAS-mutant recurrent low-grade serous ovarian cancer.

A “Rock Star” in Patient-Reported Outcomes, Is Listening

January 2nd 2025

Basch, an oncologist and researcher who moonlights as a bass player, is in tune with colleagues and patients.

Epcoritamab Is Associated With Higher Travel Burden/Costs in R/R DLBCL and Follicular Lymphoma

January 2nd 2025

Zachary Frosch, MD, MSHP, discusses the investigation of travel burden/costs related to bispecific antibodies in diffuse large B-cell lymphoma or follicular lymphoma.

A Miracle Maker in Pediatric Hematologic Cancers

January 2nd 2025

A love of collaborating with colleagues from around the globe and a fiery passion to help children diagnosed with cancer led Ching-Hon Pui, MD, to dramatically improve outcomes in pediatric oncology.

A Chance to Choose Your Own Oncology Fellows Content Adventure

January 1st 2025

Participate in the following brief inventory of relevant topics to let us know what topics you want to see explored by Oncology Fellows.

Critical Recent NCCN Guideline Updates Affect Dozens of Malignancies

December 31st 2024

Experts detail how recent NCCN guideline changes in dozens of tumor types are affecting their practices, and we gather all the NCCN updates in a slideshow.

Shipp’s Passion Leads to Transformative Research, Innovations in Lymphoma

December 31st 2024

After answering her calling for hematology oncology, Margaret A. Shipp, MD, shook up lymphoma research by exploiting the PD-1 pathway to evade immune detection and testing checkpoint inhibitors across this malignancy, among several other achievements.